Moleculin Announces Dr. James L. Abbruzzese, Chief of Medical Oncology Division at Duke University, Joins Science Advisory Bo...
January 17 2019 - 7:30AM
Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the
"Company"), a clinical stage pharmaceutical company focused on the
development of oncology drug candidates, all of which are based on
license agreements with The University of Texas System on behalf of
the M.D. Anderson Cancer Center, today announced that Dr. James L.
Abbruzzese, Chief of Oncology at Duke University has joined
Moleculin’s Science Advisory Board.
“We are honored to have Dr. Abbruzzese, a
distinguished medical oncologist join our Science Advisory Board,”
commented Walter Klemp, Moleculin’s Chairman and CEO. “Dr.
Abbruzzese is recognized as one of the world’s leading experts in
the clinical study and treatment of pancreatic cancer and the
addition of his expertise will be invaluable to our efforts on
developing a potential treatment for pancreatic cancer.”
“Pancreatic cancer is a challenging disease and
identifying new treatment options is a top priority,” said Dr.
Abbruzzese. “Moleculin has two diverse and innovative
technologies that may have the potential in treating pancreatic
cancer. I’m looking forward to working with the Moleculin
team to bring these technologies into the clinic.”
Dr. James L. Abbruzzese is the Chief of the
Division of Medical Oncology at Duke University, and Member of the
Duke Cancer Institute at Durham, North Carolina. Abbruzzese earned
his medical degree with honors from the University of Chicago
Pritzker School of Medicine and completed his residency in Internal
Medicine at Johns Hopkins Hospital. He also completed clinical
fellowships in Infectious Diseases at the Johns Hopkins and in
Medical Oncology and Medical Oncology Research Laboratory of
Neoplastic Disease Mechanisms at the Dana-Farber Cancer Institute
of Harvard Medical School. Abbruzzese has spent most of his
professional career at M.D. Anderson, where he rose through the
ranks to his current leadership positions as Chairman of the
Department of Gastrointestinal Medical Oncology and Associate
Vice-Provost for Clinical Research.
Among his many accomplishments, Abbruzzese is a
Fellow of the American College of Physicians and Fellow of the
American Society of Clinical Oncology. He has co-authored more than
400 research publications and currently serves as Chair of the
Clinical Trials and Translational Research Advisory Committee of
the National Cancer Institute. View Dr. James Abbruzzese’s
publications on PubMed:
https://www.ncbi.nlm.nih.gov/pubmed/?term=Abbruzzese+James+L
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a clinical stage
pharmaceutical company focused on the development of oncology drug
candidates, all of which are based on discoveries made at M.D.
Anderson Cancer Center. The Company’s clinical stage drugs are
Annamycin, an anthracycline designed to avoid multidrug resistance
mechanisms with little to no cardiotoxicity being studied for the
treatment of relapsed or refractory acute myeloid leukemia, more
commonly referred to as AML, and WP1066, an immuno-stimulating
STAT3 inhibitor targeting brain tumors, pancreatic cancer and AML.
Moleculin Biotech is also engaged in preclinical development of
additional drug candidates, including additional STAT3 inhibitors
and compounds targeting the metabolism of tumors.
For more information about the Company, please visit
http://www.moleculin.com.
Forward-Looking Statements
Some of the statements in this release are
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, Section 21E of the Securities Exchange Act
of 1934 and the Private Securities Litigation Reform Act of 1995,
which involve risks and uncertainties. Forward-looking statements
in this press release include, without limitation, the ability of
Moleculin’s drug technologies to show safety and efficacy in
patients. Although Moleculin Biotech believes that the expectations
reflected in such forward-looking statements are reasonable as of
the date made, expectations may prove to have been materially
different from the results expressed or implied by such
forward-looking statements. Moleculin Biotech has attempted to
identify forward-looking statements by terminology including
''believes,'' ''estimates,'' ''anticipates,'' ''expects,''
''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,''
''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or
other words that convey uncertainty of future events or outcomes to
identify these forward-looking statements. These statements are
only predictions and involve known and unknown risks,
uncertainties, and other factors, including those discussed under
Item 1A. "Risk Factors" in our most recently filed Form 10-K filed
with the Securities and Exchange Commission (“SEC”) and updated
from time to time in our Form 10-Q filings and in our other public
filings with the SEC. Any forward-looking statements
contained in this release speak only as of its date. We undertake
no obligation to update any forward-looking statements contained in
this release to reflect events or circumstances occurring after its
date or to reflect the occurrence of unanticipated events.
ContactsJoe Dorame, Robert Blum or Joe
DiazLytham Partners, LLC602-889-9700mbrx@lythampartners.com
Moleculin Biotech (NASDAQ:MBRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Moleculin Biotech (NASDAQ:MBRX)
Historical Stock Chart
From Apr 2023 to Apr 2024